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Introduction
Drug delivery through oral route is the most common 
and preferred route of drug administration both for 
solid and liquid dosage forms. However, solid dosage 
forms are popular because of the ease of administration, 
accurate dosage, self-medication, pain avoidance, and 
most importantly the patient compliance (1). Tablets 
and capsules are the most popular solid dosage forms. 
However, many people face difficulty in swallowing tablets 
and hard gelatin capsules (2). It has been found that this 
problem has been encountered in all groups of patient, but 
especially with pediatric and geriatric populations. Thus, 
these conventional dosage forms result in high incidence 
of noncompliance and ineffective therapy with respect to 
swallowing specially in the case of pediatric, geriatric, or 
any mentally retarded persons (3).
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Introduction: Rizatriptan benzoate is a potent and selective 5-HT1B/1D receptor agonist and is 
effective for the treatment of acute migraine. Difficulty in swallowing is common among all age 
groups, especially elderly and pediatrics. Orally disintegrating tablets may constitute an innovative 
dosage form that overcome the problem of swallowing and provides a quick onset of action. This 
study was aimed to formulate and evaluate an Orally Disintegrating Tablet (ODT) containing 
Rizatriptan while using semi-synthetic and natural superdisintegrants.
Methods: Orodispersible tablets were prepared by direct compression using natural 
superdisntegrant (Plantago ovata mucilage) and semi-synthetic superdisntegrant (crospovidone). 
The prepared tablets were evaluated for hardness, friability, thickness, drug content uniformity, 
water absorption and wetting time.  A 32 factorial design was used to investigate the effect of 
independent variables (amount of crospovidone and Plantago ovata mucilage) on dependent 
variables [disintegration time, wetting time and Q5 (cumulative amount of drug release after 5 
minutes)]. A counter plot was also presented to graphically represent the effect of independent 
variable on the disintegration time, wetting time and Q5. The check point batch was also prepared 
to prove the validity of the evolved mathematical model. The systematic formulation approach 
helped in understanding the effect of formulation processing variable.
Results: According to the results of optimized batches, the best concentration of superdisintegrant 
were as follows: 9.4 mg  Psyllium mucilage and 8.32 mg  crospovidone gave rapid disintegration in 
35sec and showed 99% drug release within 5 minutes.
Conclusion: Plantago ovata mucilage, a natural superdisintegrant, gives a rapid disintegration and 
high release when used with synthetic superdisntegrant in formulation of orally disintegrating 
tablet of Rizatriptan.
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It offers several advantages with respect to its stability, 
administration without water, accurate dosing, easy 
manufacturing, small packaging size, and handling (4). 
Its ease of administration in the population especially 
for pediatric, geriatric, or any mentally retarded persons 
makes it a very popular dosage form. Due to the presence 
of superdisintegrants, it gets dissolved quickly, resulting 
in rapid absorption of drug which in turn provides rapid 
onset of action (5).
Rizatriptan has a high oral bioavailability of 45%. The 
half-life is 2 to 3 hours and the Tmax is 1.5 hours for the 
conventional tablet and slightly longer for the ODT. 10 
mg dose of Rizatriptan benzoate is equipotent to a 100 mg 
of Sumatriptan, the traditional anti migraine drug. The 
bioavailability of Rizatriptan benzoate is about 45% which 
is superior to a poor 14-17% of Sumatriptan (6,7). 
In market Rizatriptan is available in freeze dried dosage 
form which gives rapid disintegration. Main disadvantage 
of this method is very costly method, process is not 
feasible and product is highly sensitive to moisture. 
Freeze drying is cumbersome and it yields a fragile and 
hygroscopic product (8).
In this study natural superdisintegrants were utilized. 
Natural superdisintegrants are safer, more biodegradable, 
better compressible, easier to preparation and cheaper and 
these advantages can boost the production of ODTs (9).
In the present study, the fast disintegrating tablets were 
prepared by the method of direct compression using 
various pharmaceutical excipients. The excipients used 
were avicel pH 102, 
crospovidone, Plantago ovata mucilage, mannitol, 
aspartame, aerosil and magnesium stearate.
Materials and Methods
Rizatriptan benzoate was bought from Farabi 
Pharmaceutical Company. Aerosil and aspartame was 
obtained as gift from Isfahan University of Medical Science 
Lab and other ingredients were bought from market.
Preparation of orally disintegrating tablets
Orally disintegrating tablet of Rizatriptan was prepared 
by direct compression method. All the ingredients were 
passed through 60 mesh sieve separately. The Rizatriptan, 
crospovidone, Psyllium mucilage, avicel PH 102, mannitol 
and aspartame were mixed up using a mortar and pestle. 
The blends were lubricated with 1% magnesium stearate 
and 1% aerosil. The blends ready for compression were 
converted into tablets. Tablets were compressed at 3 mm 
size flat round punch to get tablet machine (ErwekaAR 
4100, Germany). The compositions of experimental 
factorial design were shown in Table 1.
Methodology for isolation of Plantago ovata mucilage
For the isolation of mucilage, seeds of Plantago ovata were 
used. They were soaked in distilled water for 48 h and then 
boiled for 1 h for complete release of mucilage into water. 
The material was filtered by squeezing in a muslin cloth 
to remove marc. Then equal volume of acetone was added 
to filtrate to precipitate the mucilage. The mucilage was 
separated and dried in oven at a temperature less than 60°, 
powdered (#60 mesh), weighed and stored in desicator 
until further use (10).
32 full factorial design
Response surface methodology (RSM) was characteristi-
cally employed to relate a response variable to the levels 
of the input variables and to generate a design matrix 
to choose the optimal formulations. A statistical model, 
which consisted of interactive and polynomial terms, was 
utilized to evaluate the responses (11,12). The responses 
were analyzed using analysis of variance (ANOVA) and 
the individual response parameters were evaluated using 
F test and polynomial equation was generated for each re-
sponse using multiple linear regression analysis.
Y = b0 + b1X1 + b2X2 + b12X1X2 + b11X12 + b22X22 
Where, Y is the dependent variable, b0 is the arithmetic 
mean response of the nine runs and b1 is the estimated 
coefficient for the factor X1. The main effects (X1 and 
X2) represent the average result of changing one factor at 
a time from its low to high value. The interaction terms 
(X1 X2) show how the response changes when two factors 
are simultaneously changed. The polynomial terms (X12 
and X22) are included to investigate non-linearity. A 32 
full factorial design was employed to study the effect of 
independent variables, i.e., amount of mucilage (X1) and 
the amount of crospovidone (X2) on dependent variables 
wetting time, disintegration time and Q5 (cumulative 
amount of drug release after 5 minutes).
After application of full factorial design and with the help 
of produced polynomial terms, amount of two formulation 
variable was optimized. The optimized amount of the 
crospovidone and  Psyllium mucilage were incorporated 
in the tablet which was used as the check point of the 
regression analysis model (Tables 1 and 2).
Evaluation of Mixed Powder Blend of Drug and 
Excipients
Evaluation of mixed blends of drug and excipients were 
carried out for all the formulations for angle of repose, 
bulk density, tapped density, Hausner’s ratio and Carr’s 
index.
Bulk density (Db) and tapped density (Dt) 
Both bulk density and tapped bulk density were determined. 
A suitable amount of powder from each formulation, 
previously lightly shaken to break agglomerates formed, 
was introduced into a 10 ml measuring cylinder. After 
initial volume was observed, the cylinder was allowed 
to fall under its own weight on to a hard surface from a 
height of 2.5 cm at 2 seconds intervals. The tapping was 
continued until no further change in volume was noted. 
Bulk density and tapped bulk density were calculated 
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Table 1. Factorial design batches
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9
Rizatriptan benzoate 10 10 10 10 10 10 10 10 10
Crospovidone 3 6 9 3 6 9 3 6 9
Psyllium mucilage 6 6 6 9 9 9 12 12 12
Aerosil 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Aspartame 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Avicel PH 102 up to 150 150 150 150 150 150 150 150 150
F: formulation
Table 2. Design and summary response data
Run
Independent variable in code form
Dependent variable
Coded form Actual form
Factor A Factor B Psyllium mucilage  (mg) C.P  (mg) WT (S) DT (s) Q5 %
1 -1 -1 6 3 62 56 84
2 -1 0 6 6 59 54 93
3 -1 1 6 9 51 48 100
4 0 -1 9 3 49 45 90
5 0 0 9 6 44 41 97
6 0 1 9 9 41 37 101
7 1 -1 12 3 40 32 84
8 1 0 12 6 30 27 83
9 1 1 12 9 33 30 81
C.P: crospovidone, WT: Wetting time, DT: Disintegration time, Q5: Drug release after 5 minutes
using following formula (13):
D weight of the power
volumeof the packingb
=
t
weight of the powerD
tapped volumeof the packing
=
Carr’s index
The Compressibility Index of the powder blend was 
determined by Carr’s compressibility index. It is a Simple 
test to evaluate the Db and Dt of a powder and the rate at 
which it packed down. The formula for Carr’s Index is as 
below:
100t b
t
D DCarr index
D
−
= ×
Where Dt is tapped density of the powder and Db is bulk 
density of the powder.
Hausner’s ratio
Hausner’s ratio was calculated from bulk and tapped 
density of Rizatriptan blend powder formulation and it is 
expressed as:
' t
t
DHausner s ratio
D
=
Where Dt is tapped density and  Db  is bulk density.
Angle of repose
Angle of repose (θ) was determined using fixed funnel 
method. The height of the funnel was adjusted in such a 
way that the tip of the funnel just touched the apex of the 
heap of the granules. The granules were allowed to flow 
through the funnel freely onto the surface. The diameter 
of the granular cone was measured and angle of repose 
was calculated using the following equation:
tan h
r
θ =
Where h and r are the height and radius of the cone 
(Table 3).
Evaluation parameters of orally disintegrating tablets 
Weight variation 
Randomly, 20 tablets were selected after compression and 
the mean weight was determined (14). None of the tablets 
deviated from the average weight by more than ±7.5%.
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Table 3. Powder flow properties of the Rizatriptan formulations
Code Angle of repose (θ) Bulk density (gr/cm3) Tapped density (gr/cm3) Carr’s index (I) Hausner’s ratio
F1 31.4±0.02 0.37±0.06 0.41±0.02 10.15±1.13 1.11
F2 31±0.03 0.32±0.07 0.35±0.02 09.10±1.01 1.10
F3 30.6±0.02 0.34±0.04 0.37±0.02 07.94±0.35 1.08
F4 30.1±.003 0.36±0.02 0.39±0.02 06.63±1.27 1.07
F5 30.3±0.01 0.33±0.03 0.36±0.02 09.53±1.05 1.10
F6 29.4±0.05 0.35±0.04 0.39±0.01 09.53±1.11 1,10
F7 29±0.02 0.36±0.07 0.39±0.01 07.08±1.36 1.07
F8 29.4±0.01 0.37±0.05 0.43±0.01 14.75±1.55 1.17
F9 28.9±0.03 0.34±0.07 0.37±0.02 07.94±0.35 1.08
F: formulation
Tablet thickness
The thickness was measured by placing tablet between 
two arms of the Vernier calipers. 5 tablets were taken and 
their thickness was measured (15).
Tablet hardness
Hardness of tablet is defined as the force applied across 
the diameter of the tablet in order to break the tablet. 
The hardness of the tablets was determined by diametral 
compression using erweka Hardness Tester (16). 
Friability Testing
This test was performed to determine the effects of friction 
and shock. Pre-weighed sample of 10 tablets was placed in 
the erweka friabilator and rotated at 25 rpm for about 4 
min. The tablets were dedusted and reweighed, and the 
friability percentage was calculated. Compressed tablets 
should not lose more than 1% of weight (17).
100Initial weight Final weightPercentage friability
Initial weight
−
= ×
Wetting time
The wetting time of the tablets was measured using a simple 
procedure. Five circular tissue papers of 10-cm diameter 
were placed in a petridish with a 10-cm diameter. Ten 
milliliters of water containing eosin, a water-soluble dye, 
was added to the petridish. A tablet was carefully placed 
on the surface of tissue paper. The time required for water 
to reach the upper surface of the tablets was noted as the 
wetting time. The wetting times were measured (18)
Water absorption ratio
A piece of tissue paper folded twice was placed in a small 
petridish (Internal Diameter = 6.5 cm) containing 6 ml 
of water. A tablet was placed on the paper and the time 
required for complete wetting was then measured. The 
water absorption ratio (R) was determined using the 
following equation (19).
100a b
a
W WR
W
−
= ×
Where, Wb is the weight of the tablet before water 
absorption and Wa is the weight of the tablet after water 
absorption.
In vitro disintegration test
The in vitro disintegration studies were carried out using 
a Digital Tablet Disintegration test Apparatus (Erweka 
ZT- Germany). One tablet was placed in each of the six 
tubes of the basket assembly and then disk was added to 
each tube. This assembly was then suspended in a one-
liter beaker containing water with its temperature being 
maintained at 37±2 °C. The basket was then moved up and 
down through a distance of 5 to 6 cm, at the frequency of 
28 to 32 cycles per minute. The time required for complete 
disintegration of the tablet was recorded (20). 
Dissolution test 
The release rate of Rizatriptan benzoate from orally 
disintegrating tablets was determined using
United State Pharmacopoeia (USP) XXIV dissolution 
testing apparatus II (paddle method). The dissolution 
test was performed using 900 ml of 0.1N HCl pH 1.2 as a 
dissolution medium, at 37±0.5 ºC and 50 rpm. A sample 
(5 ml) of the solution was withdrawn from the dissolution 
apparatus at 1, 2, 3, 4, 5, 10, 20 and 30 min. The samples 
were filtered through a 0.45 membrane filter. Absorbance 
of these solutions was measured at 280 nm using a 
Shimadzu spectrophotometer. Cumulative percentage of 
drug release was calculated using an equation obtained 
from a standard curve (21).
Content uniformity
Ten tablets of each batch were weighed and powdered. 
Aliquot of this powder containing Rizatriptan benzoate 
equivalent to 5 mg of Rizatriptan was accurately weighed, 
suspended in approximately  50 ml of  0.1 N HCl and 
shaken for 15 min. Final volume was adjusted to 100 ml 
with 0.1 N HCl and filtered (Whatmann No.1 filter paper). 
From this 10 ml was diluted to 100 ml. The final volume 
was made by taking 2 ml of above solution and diluted to 
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10 ml with 0.1 N HCl. Absorbance of this solution was 
recorded at 280 nm using UV/Vis spectrophotometer 
against a reagent blank and the content was compared 
from a calibration curve prepared with standard 
Rizatriptan benzoate in the same medium (Table 4). The 
mean percent drug content was calculated as an average of 
three determinations (22).
Data analysis
Response surface model factorial designs with 2 
independent formulation variables at 3 different levels 
were used to study the effect of dependent variables (23). 
All the batches of orally disintegration were statically 
(95% or p<0.05) evaluated with regard to disintegration 
time, wetting time and drug release after 5 minutes.
Optimization of formulation ingredients
After generating the polynomial equations relating the 
dependent and independent variables, the process was 
optimized for responses, optimization was performed to 
obtain the value of X1 and X2, which targeted disintegration 
time (DT)= 35 seconds; wetting time (WT)= 40 seconds; 
drug release after 5 minutes (Q5) =99. The optimized 
amount of crospovidone and Psyllium mucilage was 
incorporated in the tablet which was also used as the check 
point of the regression analysis model (24). The optimized 
orally disintegrating tablet was prepared and evaluated for 
the physiochemical properties.
Results
Data analysis
A response surface model factorial design with 2 
independents variable at 3 different levels was used to 
study the effects in dependent variables. All the batches if 
orally disintegrating time, wetting time and drug release 
after 5 minutes. Transformed values of the batches along 
their results are show in Table 5. the dependent variables 
(DT,WT, Q5) obtained at various levels of the 2 independent 
variable (X1 and X2) were subjected to multiple regressions 
to yield a second-order polynomial equation, the obtained 
coefficient are shown in Table 5. The DT, WT and Q5 
values measured form different batches shows wide 
variation. These results clearly indicated the DT, WT and 
Q5 are strong affected by the variables selected for the 
study. This was also reflected by the wide range of value for 
coefficients of the term equation the value of correlation 
coefficient (R2) of polynomial regression equation was 
found to be greater than 0.99, indication good fit for all 
dependent variable shown in Table 5.
X1 and X2 represents the average result if changing one 
variable at a time from its low level to its high level. The 
interaction terms (X1 X2, X1 X1and X2X2) show how the DT, 
Wt and Q5 changes when 2 variables are simultaneously 
changed. Using the polynomial equations, the optimized 
formulations were obtained for the response parameters.
Polynomial equation for disintegration time
Y=43.56-14.5X1-4X2+1X1 X2+1.17X12+1.67X22
Polynomial equation for wetting time
Y=40.56-13.5X1-4 X2+1.5X1 X2+0.17X12+0.67X22
Polynomial equation for drug release after 5 minutes
Y=96.67-5X1+5.5X2-4.75X1 X2-8.5X12+1 X22
Response surface counterplot
The relationship between the dependent and independent 
variable was further elucidate by constructing counter 
plots. The effects of X1 and X2 with their interaction on DT, 
WT and Q5 at different levels (low, medium and high level) 
are displayed in Figures 1-3 .the interaction effect between 
X1 and X2 are shown in response surface plot Figures 4-6.
Optimization of orally disintegrating tablet
The optimization of the orally disintegrating tablet 
was decided to target DT= 35 sec, WT= 40 and drug 
release Q5= 99%.
Optimized concentrations were obtained from the software 
and the counter plot shown in Figure 7. Comparative 
values of predicted and observed responses along with the 
Table 4. Evaluation of the prepared orodispersible tablets of Rizatriptan
Tests F1 F2 F3 F4 F5 F6 F7 F8 F9
Weight variation  
(Mean±SD(
151±3.45 149±2.24 149±3.12 150±3.71 152±3.32 148±1.58 147±3.28 151±3.45 149±2.24
Hardness (kg/cm2( 3.81±0.25 3±0.27 3.8±0.22 3.8±.023 3.7±0.27 3.1±0.19 3.7±0.22 3±0.23 3.2±0.21
Friability 0.57±0.16 0.68±0.14 0.81±0.15 0.93±0.147 0.96±0.157 0.72±0.155 0.44±0.138 0.80±0.149 0.66±0.153 
Thickness (mm( 3.2 2.9 3.00 3.1 3.1 3.2 2.9 3.3 3.4
Wetting time (s) 62 59 51 49 44 41 40 30 33
Water absorption ratio 78.12 80.25 82.34 85.74 86.64 88.57 90.47 93 91
In-vitro disintegration 
time (s)
56 54 48 45 41 37 32 27 30
Assay 98.3 97.2 98.7 96.7 98.2 95.8 99.4 97.2 97.3 
F: formulation
Tabbakhian M et al.
Journal of HerbMed Pharmacology, Volume 3, Number 1, June 2014 http://www.herbmedpharmacol.com 26
Table 5. Analysis of variance (ANOVA) response surface cubic model
Source Sum of squares Df Mean square F value Prob of P value< F value R2
For Wetting time
Model 945.78 7 135.11 304.00 0.0441 0.9995
X1 420.50 1 420.50 946.13 0.0207
X2 32.00 1 32.00 72.00 0.0747
X1X2 4.00 1 4.00 9.00 0.2048
X1
2 2.72 1 2.72 6.12 0.2445
X2
2 5.56 1 5.56 12.50 0.1755
Residual 0.44 1 0.44
Cor total 946.22 8
For Disintegration 
time
Model 872.44 7 124.63 280.43 0.0459 0.9995
X1 364.50 1 364.50 820.13 0.0222
X2 32.00 1 32.00 72.00 0.0747
X1X2 9.00 1 9.00 20.25 0.1392
X1
2 0.00 1 0.00 0.12 0.7837
X2
2 0.00 1 0.00 2.00 0.3918
Residual 0.44 1 0.44
Cor total 872.89 8
For Drug release 
after 5 minutes
Model 479.75 7 68.54 274.14 0.0465 0.9995
X1 50.00 1 50.00 200.00 0.0449
X2 60.50 1 84.50 760.50 0.0231
X1X2 90.25 1 90.25 361.00 0.0335
X1
2 144.50 1 144.50 578.00 0.0265
X2
2 2.00 1 2.00 8.00 0.2163
Residual 0.25 1 0.25
Cor total 480.00 8
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Figure 1. Counter plot for wetting time. WT: Wetting time, X1=A: 
P.M, X2=B:C.P, C.P: crospovidone, P.M: Psyllium mucilage.
Figure 2. Counter plot for disintegration time. X1=A: P.M, 
X2=B:C.P; C.P: crospovidone, P.M: Psyllium mucilage, DT: 
disintegration time.
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Figure 3. Counter plot for Q5. X1=A: P.M, X2=B:C.P, C.P: 
crospovidone, P.M: Psyllium mucilage, Q5: drug release after 5 
minutes.
Figure 4. Response surface plot for wetting time. WT: Wetting 
time,X1=A: P.M, X2=B:C.P, C.P: crospovidone, P.M: Psyllium 
mucilage.
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Figure 6. Response surface plot for Q5. X1=A: P.M, X2=B:C.P, 
C.P: crospovidone, P.M: Psyllium mucilage, Q5: drug release after 
5 minutes. 
Figure 5. Response surface plot for Disintegration time. DT: 
Disintegration time, X1=A: P.M, X2=B:C.P, C.P: crospovidone, 
P.M: Psyllium mucilage.
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Figure 7. Counter plot for desirability. X1=A: P.M, X2=B:C.P, C.P: 
crospovidone, P.M: Psyllium mucilage.
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formulation components are reported in Table 6. 
Discussion
An optimized formulation of Rizatriptan orally 
disintegrating tablet was  prepared in this study using 
the “Direct compression” method. Formulation and 
optimization procedures were facilitated using 32 full 
factorial designs.
About the WT and DT tests, it was observed that with 
increasing crospovidone and Psyllium mucilage DT 
and WT was both decreased; however, changes in the 
quantities of Psyllium mucilage had more significant 
effect than crospovidone (10).
On the other hand with increasing the percentage of 
Psyllium mucilage, speed of drug release was decreased, 
hence to create a suitable response, an optimum limit 
in usage Psyllium mucilage was found to have a proper 
amount of drug release.
Tabbakhian M et al.
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Table 6. Comparative value of predicted and observed responses.
F.NO
Psyllium mucilage 
(mg(
crospovidone 
(mg(
DT (Sec( WT Q5 Desirability
Predicted Observed Predicted Observed Predicted Observed
O1 9.40 8.32 36.47 36.3 39.99 39.2 99.00 99.12 0.976
WT: Wetting time, DT: Disintegration time, Q5: drug release after 5 minutes, O: Optimized batch
Effect of formulation vaiable on WT
Value of prob>f less than 0.05 show the model for WT 
is significant and Factor X1 is found to be significant in 
this case. The negative coefficient for X1 and X2 indicate 
favorable effect on WT [increasing the amount of C.P and 
P.M (Psyllium mucilage) decrease the WT]. The results 
convey us that factor X1 has significant effect on WT than 
that of X2.
Effect of formulation vaiable on DT
Value of prob>f less than 0.05 show the model terms are 
significant and  Factor X1 is found to be significant in 
this case The negative coefficient for X1 and X2 indicate 
favorable effect on DT (increasing the amount of C.P and 
P.M decrease the DT). The results convey us that factor X1 
has significant effect on DT than that of X2.
Effect of formulation vaiable on Q5
Value of prob>f less than 0.05 show the model for Q5 
is significant and factor X1, X2, and X1X2 and X12 are 
significant. The positive coefficient for X2 indicates 
favorable effect on WT (increasing the amount of C.P 
increase the Q5). The results convey us that factor X2 has 
significant effect on Q5 than that of X1.
Conclusion
Overall, the results convey us that optimized orally 
disintegrating tablets of Rizatriptan containing 9.4 mg of 
C.P and 8.32 mg of P.M as a superdisntegrant by direct 
compression method showed responses as we desired.
Acknowledgments 
Authors would like to thank the financial support offered 
by school of pharmacy and pharmaceutical science of 
Isfahan University of medical Sciences.
Authors’ contributions
All contributed in the study, MT, MAS and ESh prepared 
the manuscript and Mk edited it.
Conflict of interests 
The authors declared no competing interests.
Ethical considerations 
Ethical issues (including plagiarism, data fabrication, 
double publication) have been completely observed by the 
authors.
Funding/Support
None.
References
1. Paramita D and Sabyasachi M. Orodispersible tablets: 
A new trend in drug delivery. J Nat Sci Biol Med 2010; 
1(1): 2–5.
2. Lindgren S, Janzon L. Dysphagia: Prevalence of 
swallowing complaints and clinical finding. Med Clin 
North Am 1993;77:3–5.
3. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast 
disintegrating tablets: Developments, technologies, 
taste-masking and clinical studies. Crit Rev Ther 
Drug Carrier Syst 2004; 21:433–76.
4. Bandari S, Mittapalli RK, Gannu R, Rao YM. 
Orodispersible tablets: An overview. Asian Journal of 
Pharmaceutics 2008;2:2–11.
5. Behnke K, Sogaard J, Martin S, Bauml J, Ravindran 
AV, Agren H. Mitrazapine orally disintegrating tablet 
versus sertraline: A prospective onset of action study. 
J Clin Psychopharmacol 2003; 23:358–64.
6. Krymchantowski AV, Bigal ME.  Rizatriptan versus 
Rizatriptan plus rofecoxib versus rizatriptan plus 
tolfenamic acid in the acute treatment of migraine. 
BMC Neurol 2004;4:10.
7. Sanders-Bush E, Mayer SE. 5-hydroxytryptamine 
(Serotonin): Receptor agonists & antagonists. In: 
Brunton LL, Lazo JS, Parker KL, editors. Goodman & 
Gilman’s The Pharmacological Basis of Therapeutics. 
11th ed. New York: McGraw Hill; 2006:305–9.
8. Mahajan HS, Kuchekar BS, Badhan AC. Mouth 
dissolve tablets of Sumatriptan succinate. Indian J 
Pharm Sci 2004;66(2):238-40.
9. Mohan GV, Prassad DS, Kumar NR, Murty KV. 
Nimesulide Modified gum karaya solid mixture: 
Preparation, characterization, and formulation 
development. Drug Develop Ind Pharm 2003; 
855:864-29.
10. Aveja SK, Rao KV, Arora J. Examination of natural 
gums and mucilages as sustaining materials in tablet 
dosage forms-II. Indian J Pharm Sci 1989; 51:115–8.
11. Singh B, Bhatowa R, Tripathi CB, Kapil R. Developing 
micro-/nanoparticulate drug delivery systems 
using “design of experiments”. Int J Pharm Investig 
2011;1:75–87
12. Bi Y, Sunada H, Danjo K, Yonezawa Y. Evaluation 
of rapidly disintegrating tablet prepared by a direct 
compression method. Drug Dev Ind Pharm 1999; 25: 
Formulation of Rizatriptan using natural superdisintegrant
Journal of HerbMed Pharmacology, Volume 3, Number 1, June 2014http://www.herbmedpharmacol.com 29
571-58.
13. Lieberman HA, Lachman L. Pharmaceutical dosage 
forms tablets.  2nd edition. New York: Marcel 
Dekker;1989. p. 198-9.
14. Indian Pharmacopoeia, Vol‐2. The Controller of 
Publication Delhi;1996. p. 735.
15. Banker GS, Anderson NR. In: Lachman L, Lieberman 
HA, Kanig JL, editors. The Theory and Practice 
of Industrial Pharmacy. 3rd ed. Mumbai:Varghese 
Publishing House;1987. p. 293-399.
16. Arora P, Arora V. Orodispersible tablets: A 
comprehensive review. International Journal of 
Pharmaceutical Sciences and Research 2013;2(2): 
270-84.
17. Nawale RB, Mohite KP.   Formulation and evaluation 
of domperidone orodispersible tablet. International 
Journal of Pharmaceutical Sciences and Research 
2013; 4(9):3670-7.
18. Bandari S, Mittapalli RK, Gannu R, Rao YM. 
Orodispersible tablets: An overview. Asian Journal of 
Pharmaceutics 2008;2(1):2-11.
19. Kundu S, Sahoo PK. Recent trends in the developments 
of orally disintegrating technology. Pharma Times 
2008; 40:11-5.
20. United States Pharmacopeia, National Formulary 
USP29/NF24. Rockville: The United States 
Pharmacopeia Convention; 2006.
21. United State Pharmacopoeia. Convention. NF Asian 
edition. 2004,  p. 74-75.
22. Indian Pharmacopoeia. 4th ed. New Delhi: The 
Controller of Publications; 1996. p. 735–6.
23. Gohel M, Patel M, Amin A, Agrawal R, Dave R, Bariya 
N. Formulation design and optimization of mouth 
dissolve tablets of nimesulide using vacuum drying 
technique. AAPS Pharm Sci Tech 2004; 5(36):1-6.
24. Shimizu T, Sugaya M, Nakano Y. Formulation study 
for lansoprazol fast disintegrating tablet, III.design 
rapidly disintegrating tablets. Chem pharm Bull 
2003;51:1121-7.
